These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19101793)

  • 21. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
    Miller WR; Bartlett J; Brodie AM; Brueggemeier RW; di Salle E; Lønning PE; Llombart A; Maass N; Maudelonde T; Sasano H; Goss PE
    Oncologist; 2008 Aug; 13(8):829-37. PubMed ID: 18695261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extending the benefits of adjuvant therapy in early HR+ breast cancer.
    Goss PE
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():45-52. PubMed ID: 18785006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
    Toi M; Yamashiro H; Tsuji W
    Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of third-generation aromatase inhibitors on bone.
    McCloskey E
    Eur J Cancer; 2006 May; 42(8):1044-51. PubMed ID: 16554149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
    Dixon JM
    Breast; 2008 Aug; 17(4):353-60. PubMed ID: 18490163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in adjuvant endocrine therapy for postmenopausal women.
    Lin NU; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
    Ewer MS; Glück S
    Cancer; 2009 May; 115(9):1813-26. PubMed ID: 19235248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
    Jonat W; Mundhenke C
    Cancer Invest; 2007 Feb; 25(1):14-8. PubMed ID: 17364552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of adjuvant aromatase inhibitor therapy.
    Venturini M; Del Mastro L
    Cancer Treat Rev; 2006 Nov; 32(7):548-56. PubMed ID: 17008013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The similarities of aromatase inhibitors outweigh the differences.
    Jänicke F
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S7-9. PubMed ID: 18337642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating elderly patients with hormone sensitive breast cancer: what do the data show?
    Balducci L
    Cancer Treat Rev; 2009 Feb; 35(1):47-56. PubMed ID: 18840391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.
    Jhaveri K; Halperin P; Shin SJ; Vahdat L
    Breast Cancer Res Treat; 2007 Dec; 106(3):315-8. PubMed ID: 17972174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
    Gligorov J; Pritchard K; Goss P
    Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Facilitating breast-conserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings.
    Mamounas EP
    Ann Surg Oncol; 2008 Mar; 15(3):691-703. PubMed ID: 18196346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translating trial data into patients benefits: making the right choice.
    Chlebowski RT
    Breast; 2008 Apr; 17 Suppl 3():S9-15. PubMed ID: 18367397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression of endocrine therapies for breast cancer: where are we headed?
    Arnedos M; Smith I
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1651-64. PubMed ID: 18020931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.
    Howell A; Dowsett M
    Breast Cancer Res; 2004; 6(6):269-74. PubMed ID: 15535858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Menopausal symptoms and adjuvant therapy-associated adverse events.
    Hadji P
    Endocr Relat Cancer; 2008 Mar; 15(1):73-90. PubMed ID: 18310277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.